Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 34

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 34
---
 in the ATM Offering to $2,295,192 in the aggregate, inclusive of the shares of Common Stock previously sold in the ATM Offering. The offer and sale of shares of Common Stock from the ATM Offering were made pursuant to our effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-280796) which became effective on July 18, 2024. From July 19, 2024 to August 2, 2024, the Company sold a total of 135,568 shares in the ATM Offering for gross proceeds of $1,994,583. 18

Summary Risk Factors Our business is subject to a number of risks. You should be aware of these risks before making an investment decision. These risks are discussed more fully in the section of this prospectus titled “ Risk Factors,” which begins on page 23 of this prospectus. These risks include, among others, that:

| ● | Our                                                                                           
 financial statements have been prepared on a going-concern basis and our continued operations 
 are in doubt;                                                                                 |

| ● | We                                                                                         
 have incurred net losses since our inception and if we continue to incur net losses in the 
 foreseeable future, the market price of our common stock may decline;                      |

| ● | There                                       
 is no assurance that we will be profitable; |

| ● | There                                                                                       
 is no assurance that we will be eligible for Australian government research and development 
 tax rebates;                                                                                |

| ● | Our                                                                                  
 financial condition and results of operations may be adversely affected by COVID-19; |

| ● | If                                                                                                      
 we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization 
 of non-malaria prevention indications for Tafenoquine (Arakoda or other regimen) or Celgosivir          
 in a timely manner, we may not be able to expand our business operations;                               |

| ● | Our                                                                                             
 clinical trials for our product candidates may not yield results that will enable us to further 
 develop our products and obtain regulatory approvals necessary to sell them;                    |

| ● | We                                                                                            
 expect to depend on existing and future collaborations with third parties for the development 
 of some of our product candidates. If those collaborations are not successful, we may not     
 be able to complete the development of these product candidates;                              |

| ● | Even                                                                                              
 if one of our product candidates receives marketing approval, it may fail to achieve the